Shares of Terns Pharmaceuticals, Inc. (TERN) have gained 3.7% over the past four weeks to close the last trading session at $7.95, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $14.21 indicates a potential upside of 78.7%. The average comprises seven short-term price targets ranging from a low of $5.50 to a high of $22, with a standard deviation of $5.92. While the lowest esti ...

Company Leadership Changes - Elona Kogan has been appointed as the chief legal officer of Terns Pharmaceuticals, bringing over 20 years of experience in the life sciences sector, including pivotal roles in IPOs and commercialization at Seer, Inc. and other pharmaceutical companies [1][6] - Mark Vignola, the current chief financial officer, will leave the company in a planned transition, continuing until a successor is found, expected to be by the end of January 2025 [2][3] Company Pipeline and Development - Terns Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing small-molecule product candidates targeting serious diseases such as oncology and obesity [3][6] - The company's pipeline includes three clinical-stage development programs: an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, and a THR-β agonist, along with a preclinical GIPR modulator program [3]

FOSTER CITY, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of smallmolecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Elona Kogan, Esq., as chief legal officer, effective immediately. Ms. Kogan brings a wealth of industry experience and has successfully guided several biotechnology companies through trans ...

"While GLP-1 receptor agonists facilitate weight loss by suppressing food intake, efficacy may be limited by metabolic adaptation, a counter regulatory process that lowers energy expenditure in response to weight loss. THR-β agonism, an orthogonal mechanism to GLP-1, appears to unlock additional efficacy of GLP-1 therapies by normalizing energy expenditure during weight loss, while preserving relative lean mass," said Emil Kuriakose, M.D., chief medical officer at Terns. "These exciting results suggest that ...

About TERN-501 FOSTER CITY, Calif., June 21, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of smallmolecule product candidates to address serious diseases, including oncology and obesity, today announced that preclinical data supporting TERN-501, a highly selective thyroid hormone receptor beta (THR-β) receptor agonist, in combination with a GLP-1 receptor agonist for obesity will be highlight ...

Company Overview - Terns Pharmaceuticals, Inc. (TERN) is a clinical-stage biopharmaceutical company focusing on developing small molecule product candidates in oncology and obesity [4][11]. - The company has a promising pipeline that includes TERN-701, an allosteric BCR-ABL inhibitor for chronic myeloid leukemia (CML), and TERN-601, a GLP-1 receptor agonist for obesity [5][14]. Financial Performance - Terns has shown a year-to-date (YTD) stock price increase of 13.6%, outperforming the industry, which has declined by 7% [10][17]. - As of March 31, 2024, Terns reported cash, cash equivalents, and marketable securities totaling $240.7 million, which is expected to fund its operations into 2026 [7]. Pipeline Development - TERN-701 has demonstrated superior efficacy and safety compared to traditional tyrosine kinase inhibitors, with ongoing phase I trials showing promising results [5][12]. - The company is also conducting a phase I study (CARDINAL) for TERN-701 in CML, with interim data expected in the second half of 2024 [18]. - Terns plans to report top-line 28-day weight loss data for TERN-601 in the second half of 2024, capitalizing on the lucrative obesity market [21]. Regulatory Progress - In March 2024, TERN-701 received orphan drug designation from the FDA for the treatment of CML, which may enhance its market potential [19]. Competitive Landscape - TERN-701 is positioned as a differentiated treatment option compared to Novartis' Scemblix, offering more convenient dosing for CML patients [6][20]. - The company is also exploring the potential of GIPR antagonist combinations for obesity treatment, indicating a strategic focus on innovative therapies [16].

Shares of Terns Pharmaceuticals, Inc. (TERN) have gained 3.8% over the past four weeks to close the last trading session at $6.01, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $14.21 indicates a potential upside of 136.4%. The mean estimate comprises seven short-term price targets with a standard deviation of $5.92. While the lowest estimate of $5.50 indicates an 8.5% decline ...

The Company granted to Scott Harris, the Company's new Chief Development Officer, an option to purchase 475,000 shares of Terns common stock as of May 28, 2024, and to the other non-executive employee an option to purchase 36,000 shares of Terns common stock as of June 1, 2024. FOSTER CITY, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small molecule product candidates to a ...

FOSTER CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small molecule product candidates to address serious diseases, including oncology and obesity, today announced that members of senior management will be participating in the following upcoming investor conferences in June. Jefferies Global Healthcare Conference Format: Fireside Chat Date and Time: Wednesday, June 5, ...

FOSTER CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small molecule product candidates to address serious diseases, including oncology and obesity, today announced that members of senior management will be participating in the following upcoming investor conferences in June. Jefferies Global Healthcare Conference Format: Fireside Chat Date and Time: Wednesday, June 5, ...